McKesson (MCK) shares soared 3.2% in the last trading session to close at $194.36. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% loss over the past four weeks.
McKesson witnessed solid price appreciation following the news of the New York Attorney General Letitia James’ announcement of a $1.1 billion settlement agreement with three of the nation’s largest drug distributors, McKesson being one of them. This will help the New York State to combat the ongoing opioid epidemic. Market is also optimistic about the company’s deal with the PHOENIX group to sell its European businesses in France, Italy, Ireland, Portugal, Belgium and Slovenia to the latter.
This prescription drug distributor is expected to post quarterly earnings of $4.15 per share in its upcoming report, which represents a year-over-year change of +49.8%. Revenues are expected to be $59.6 billion, up 7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For McKesson, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MCK going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McKesson Corporation (NYSE:MCK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research